Pepper, Christopher - Cardiff University

个人简介

I am currently Dean of Research in the School of Medicine in Cardiff where I run a successful leukaemia research team. For the past 21 years my research has predominantly focussed on one type of leukaemia, chronic lymphocytic leukaemia (CLL). During which time I has published over 100 Peer reviewed papers and have been an invited speaker at numerous national and international meetings. My research team is currently funded by Bloodwise, Cancer Research UK, Leukaemia Research Appeal for Wales and Worldwide Cancer Research.

研究领域

For the past 21 years my research career has been focussed on one disease, chronic lymphocytic leukaemia (CLL). CLL represents an unrivalled primary human tumour model for investigating apoptotic signalling pathways and the molecular mechanisms that promote drug resistance. Consequently, these two areas of investigation are the focus of my team. We were the first group to describe the pivotal role of the Bcl-2 family of apoptosis-regulating proteins in determining the clinical outcome of CLL and this family of proteins still forms a significant part of our research programme. In addition, we have a strong interest in B-cell receptor and co-receptor signalling as well as PI3K and NF-kB signalling. Most recently, we have been addressing questions relating to cytogenetic instability and clonal evolution in collaboration with Professor Duncan Baird and this has resulted in the formation of a University spin-out company to provide prognostic and predictive testing for cancer patients. Our research is almost entirely patient-focussed; most of our work is based on primary CLL cells derived from patients and even our basic research has a strong translational element designed to improve patient care. In this regard, we were the first to demonstrate the clinical importance of the protein biomarkers Rel A and Mcl-1. We also have a strong track record of developing novel pre-clinical agents into early phase clinical trials examples include Bcl-2 antisense oligonucleotides, the cyclin-dependent kinase inhibitor flavopiridol and the NF-kB inhibitor LC-1.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Pepper, C.et al. 2017. Tumor cell migration is inhibited by a novel therapeutic strategy antagonizing the alpha-7 receptor. Oncotarget (10.18632/oncotarget.14545) pdf Williams, J.et al. 2017. Telomere length is an independent prognostic marker in MDS but not in de novo AML. British Journal of Haematology pdf Hyatt, S.et al. 2017. Telomere length is a critical determinant for survival in multiple myeloma. British Journal of Haematology pdf Parry, H.et al. 2016. Cytomegalovirus infection does not impact on survival or time to first treatment in patients with Chronic Lymphocytic Leukaemia. American Journal of Hematology 91(8), pp. 776-781. (10.1002/ajh.24403) Pasikowska, M.et al. 2016. Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. Blood (10.1182/blood-2016-01-683128) Nichols, E.et al. 2015. A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL. Oncotarget 6(32), pp. 32669-32680. (10.18632/oncotarget.5404) Simpson, K.et al. 2015. Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients. Molecular Oncology 9(6), pp. 1186-1193. (10.1016/j.molonc.2015.02.003) pdf Reid, R.et al. 2015. CD8+ T-cell recognition of a synthetic epitope formed by t-butyl modification. Immunology 144(3), pp. 495-505. (10.1111/imm.12398) pdf Reid, R.et al. 2015. CD8+T-cell recognition of a synthetic epitope formed byt-butyl modification. Immunology 144(3), pp. 495-505. (10.1111/imm.12398) Fegan, C. D. and Pepper, C. J. 2015. Understanding cancer cell survival is key to patient survival. The Lancet Oncology 16(2), pp. 122-124. (10.1016/S1470-2045(15)70003-3)